Opko Health Inc (OPK)

NASD · Healthcare · Diagnostics & Research · USA

Opko Health Inc is a small cap company (market value between $300 million and $2 billion) in the Diagnostics & Research industry.

Opko Health is a diversified healthcare company with pharmaceutical and diagnostics operations. Its pharmaceutical business includes NGENLA, a once-weekly growth hormone injection developed with Pfizer, and Rayaldee for treating secondary hyperparathyroidism in chronic kidney disease patients. The company owns ModeX Therapeutics, developing immunotherapies for cancer and infectious diseases, and operates manufacturing platforms in Spain, Ireland, Chile, and Mexico.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Opko Health Inc stock.

Our verdict on OPK

Not valued: We cannot value this company yet.

We do not publish a value for this company: not even its current assets cover what it owes.

ETFs with the most weight in OPK

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Diagnostics & Research

All 44 Diagnostics & Research stocks

Cheaper than OPK in Diagnostics & Research

23 more in this industry show a wider margin of safety.

Is OPK undervalued or overvalued?

We do not publish a verdict on OPK yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of OPK?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.